Of note, EGR2 mutations have been detected in clinically aggressive CLL subgroups [37] while E2F4, a key regulator of the cell cycle, has been reported deregulated in both Burkitt lymphoma and diffuse large B cell lymphoma [38]. This evidence concerns the gene EGR2 and B-cell chronic lymphocytic leukemia.